Status:

UNKNOWN

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

Lead Sponsor:

Fayoum University

Collaborating Sponsors:

Cairo University

Conditions:

SGLT2i Kideny Protection Against Contrast in Diabetic Kidney

Eligibility:

All Genders

30+ years

Brief Summary

We will look for the possible effect of SGLT2i as a single agent to prevent post-contrast Acute Kidney Injury in diabetic kidney disease.

Detailed Description

Population of Study o Group 1 : 1. st group will receive normal saline 10ml/kg over 6 hours before and 6 hours after radiocontrast. o Group 2 : 2. nd group will receive allopurinol 300 mg and lin...

Eligibility Criteria

Inclusion

  • Age: more than30years, Diabetes, Diabetic kidney disease, GFR: more than30ml/min/1.73m2

Exclusion

  • Diabetics Patients with GFR less than 30 mL/min/1.73 m2.

Key Trial Info

Start Date :

July 1 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

August 1 2024

Estimated Enrollment :

800 Patients enrolled

Trial Details

Trial ID

NCT04853615

Start Date

July 1 2021

End Date

August 1 2024

Last Update

April 26 2021

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease? | DecenTrialz